HOLY CROSS HOSPITAL
- Type
- Teaching hospital
- Where
- SILVER SPRING, MD
- Medicare CCN
- 210004
- Received
- $1,365,883 in 69 records, 2019 ($746 general, $1,365,136 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: HOLY CROSS HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: HOLY CROSS HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 9 | $746 |
| 2019 | Research payment | 60 | $1,365,136 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| TESARO, Inc. | 36 | $1,146,917 | 2019 |
| AstraZeneca Pharmaceuticals LP | 6 | $85,920 | 2019 |
| PFIZER INC. | 4 | $72,480 | 2019 |
| Medtronic, Inc. | 10 | $36,550 | 2019 |
| Novartis Pharmaceuticals Corporation | 1 | $13,910 | 2019 |
| AstraZeneca UK Limited | 1 | $8,100 | 2019 |
| SANOFI US SERVICES INC. | 1 | $1,000 | 2019 |
| CSL Behring | 1 | $500 | 2019 |
| Zimmer Biomet Holdings, Inc. | 1 | $258 | 2019 |
| KARL STORZ Endoscopy-America | 7 | $210 | 2019 |
| American National Red Cross | 1 | $36 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 60 | $1,365,136 |
| Space rental or facility fees (teaching hospital only) | 1 | $500 |
| Gift | 7 | $210 |
| Food and Beverage | 1 | $36 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $12,394 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenanc | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $6,874 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2019 |
| 2019-12-09 | TESARO, Inc. | $18,650 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-12-04 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-11-26 | TESARO, Inc. | $53,524 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-11-26 | Medtronic, Inc. | $5,430 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | PSR-TDD | 2019 |
| 2019-11-26 | Medtronic, Inc. | $1,858 | Research payment | Cash or cash equivalent | PISCES Device, Spinal Cord Neurostimulation | PSR-PSTM | 2019 |
| 2019-11-22 | Novartis Pharmaceuticals Corporation | $13,910 | Research payment | Cash or cash equivalent | PIQRAY Drug, ONCOLOGY | A PHASE II MULTICENTER OPEN LABEL TWO COHORT NON COMPARATIVE STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB PLUS F | 2019 |
| 2019-11-21 | PFIZER INC. | $39,281 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2019 |
| 2019-11-18 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-11-08 | American National Red Cross | $36 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-16 | TESARO, Inc. | $41,048 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-10-14 | TESARO, Inc. | $53,524 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-09-16 | CSL Behring | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-08-29 | TESARO, Inc. | $26,762 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-08-26 | Medtronic, Inc. | $7,145 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | PSR-TDD | 2019 |
| 2019-08-26 | Medtronic, Inc. | $2,547 | Research payment | Cash or cash equivalent | PISCES Device, Spinal Cord Neurostimulation | PSR-PSTM | 2019 |
| 2019-08-13 | TESARO, Inc. | $53,524 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-08-12 | TESARO, Inc. | $69,136 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-07-29 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | PSR-TDD | 2019 |
| 2019-07-29 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | PISCES Device, Spinal Cord Neurostimulation | PSR-PSTM | 2019 |
| 2019-07-18 | TESARO, Inc. | $15,301 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-07-18 | TESARO, Inc. | $205 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-07-16 | TESARO, Inc. | $20,310 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-07-10 | TESARO, Inc. | $51,852 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-07-09 | AstraZeneca Pharmaceuticals LP | $45,745 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2019 |
| 2019-07-01 | TESARO, Inc. | $53,524 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-06-19 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-05-29 | TESARO, Inc. | $69,136 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-05-29 | Medtronic, Inc. | $6,423 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | PSR-TDD | 2019 |
| 2019-05-29 | Medtronic, Inc. | $1,107 | Research payment | Cash or cash equivalent | PISCES Device, Spinal Cord Neurostimulation | PSR-PSTM | 2019 |
| 2019-05-21 | TESARO, Inc. | $40,143 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-05-21 | TESARO, Inc. | $60 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-05-20 | TESARO, Inc. | $17,284 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-05-10 | TESARO, Inc. | $1,755 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-05-10 | TESARO, Inc. | $1,701 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-05-10 | TESARO, Inc. | $750 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-05-08 | PFIZER INC. | $8,000 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2019 |
| 2019-05-06 | TESARO, Inc. | $51,852 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-05-02 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | FLEXIBLE CYSTOSCOPE, CHNL:7FR, 15FRX37CM Device, UROLOGY | 2019 | |
| 2019-04-29 | TESARO, Inc. | $31,285 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-04-15 | TESARO, Inc. | $51,852 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-04-02 | TESARO, Inc. | $18,680 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-04-02 | TESARO, Inc. | $5,990 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-03-26 | AstraZeneca Pharmaceuticals LP | $15,250 | Research payment | Cash or cash equivalent | TAGRISSO Drug, Oncology | A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenanc | 2019 |
| 2019-03-26 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | CCU,MODULAR,H3-LINK,US Device, VIDEOIMAGING | 2019 | |
| 2019-03-25 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-03-18 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-03-18 | SANOFI US SERVICES INC. | $1,000 | Research payment | Cash or cash equivalent | ZALTRAP Drug, ONCOLOGY | Prospective international observational cohort non-comparative study describing the safety and effectiveness of ZALTRAP? | 2019 |
| 2019-03-18 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | RHINO-LARYNGOSCOPE, FLEX,11 FR. X 300 Device, ENT | 2019 | |
| 2019-03-18 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | CCU,MODULAR,H3-LINK,US Device, VIDEOIMAGING | 2019 | |
| 2019-03-07 | AstraZeneca UK Limited | $8,100 | Research payment | Cash or cash equivalent | LYNPARZA Drug, Oncology | To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients | 2019 |
| 2019-03-05 | TESARO, Inc. | $12,620 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-02-26 | TESARO, Inc. | $26,762 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-02-26 | TESARO, Inc. | $14,000 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY | 2019 |
| 2019-02-25 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-02-25 | PFIZER INC. | $2,196 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2019 |
| 2019-02-22 | AstraZeneca Pharmaceuticals LP | $5,653 | Research payment | Cash or cash equivalent | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2019 |
| 2019-02-19 | Zimmer Biomet Holdings, Inc. | $258 | Research payment | Cash or cash equivalent | Comprehensive Nano Device, Extremities | Comprehensive Shoulder System with Nano Humeral Component IDE Study | 2019 |
| 2019-02-15 | Medtronic, Inc. | $9,313 | Research payment | Cash or cash equivalent | SYNCHROMED Device, Drug Infusion Systems | PSR-TDD | 2019 |
| 2019-02-15 | Medtronic, Inc. | $1,724 | Research payment | Cash or cash equivalent | PISCES Device, Spinal Cord Neurostimulation | PSR-PSTM | 2019 |
| 2019-02-13 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | ELECTRODE,DISSECTING L-SHAPED, Device, LAPAROSCOPY | 2019 | |
| 2019-02-06 | PFIZER INC. | $23,003 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT | 2019 |
| 2019-01-29 | TESARO, Inc. | $69,136 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-01-22 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-01-21 | TESARO, Inc. | $17,284 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-01-21 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | STROBO VIDEO,MIC,FOOTSWITCH LOYAL KT Device, ENT | 2019 | |
| 2019-01-07 | TESARO, Inc. | $51,852 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Silver Spring, MD, county Montgomery County, MD, state Maryland; placed by its city name.
| Measure | Place (city or town) Silver Spring, MD | County Montgomery County, MD | State Maryland |
|---|---|---|---|
| Population B01003 | 81,462 | 1,065,949 | 6,206,011 |
| Population, 2020 census P1 | 81,015 | 1,062,061 | 6,177,224 |
| Median age B01002 | 35.6 | 40.2 | 39.4 |
| Under 18 B01001 | 22.2% | 22.8% | 22.2% |
| 65 and over B01001 | 12.1% | 17.0% | 16.7% |
| Households B11001 | 33,988 | 389,210 | 2,362,928 |
| Foreign born B05002 | 33.9% | 33.6% | 16.6% |
| Median household income B19013 | $99,860 | $132,450 | $103,678 |
| Median family income B19113 | $126,101 | $164,096 | $127,817 |
| Per capita income B19301 | $57,635 | $67,571 | $52,979 |
| Poverty rate B17001 | 10.6% | 7.5% | 9.4% |
| Unemployment rate B23025 | 5.4% | 4.9% | 4.9% |
| Civilian labor force B23025 | 50,814 | 590,776 | 3,313,651 |
| Mean commute (minutes) B08013 | 34.0 | 31.9 | 31.1 |
| Bachelor's degree or higher B15003 | 60.6% | 60.6% | 43.4% |
| Housing units B25001 | 35,774 | 406,531 | 2,560,784 |
| Owner-occupied B25003 | 38.3% | 65.3% | 67.6% |
| Renters B25003 | 61.7% | 34.7% | 32.4% |
| Median home value B25077 | $643,300 | $640,300 | $419,900 |
| Median gross rent B25064 | $1,913 | $2,068 | $1,705 |
| White, not Hispanic B03002 | 32.8% | 39.5% | 46.6% |
| Black B03002 | 28.3% | 18.3% | 28.9% |
| Hispanic or Latino B03002 | 24.5% | 21.0% | 12.5% |
| Asian B03002 | 8.5% | 15.3% | 6.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Silver Spring, MD.
Comments